Erickson v. Biogen, Inc

District Court, W.D. Washington·Decided October 16, 2019·No. 2:18-cv-01029·Unknown

Opinion

THE HONORABLE JOHN C. COUGHENOUR 1 2 3 4 5 6 UNITED STATES DISTRICT COURT 7 WESTERN DISTRICT OF WASHINGTON 8 AT SEATTLE 9 DANITA ERICKSON, CASE NO. C18-1029-JCC 10 Plaintiff, ORDER 11 v. 12 BIOGEN, INC., 13 Defendant. 14

15 This matter comes before the Court on Plaintiff Danita Erickson’s motion for partial 16 summary judgment (Dkt. No. 48) and Defendant Biogen, Inc.’s motion for summary judgment 17 (Dkt. No. 50). Having thoroughly considered the parties’ briefing and the relevant record, the 18 Court finds oral argument unnecessary and hereby GRANTS in part and DENIES in part 19 Plaintiff’s motion and DENIES Defendant’s motion for the reasons explained herein. 20 I. BACKGROUND 21 Defendant is a pharmaceutical company that produces and markets products to treat 22 serious diseases, primarily multiple sclerosis. (See Dkt. No. 1 at 2.) In 2011, Defendant hired 23 Plaintiff to work in its sales division as a territory business manager (“TBM”). (Dkt. No. 51 at 24 90–91.) She was responsible for a territory within Defendant’s Northwest region, which includes 25 Washington, Oregon, Idaho, and Alaska. (Id.) The Northwest region had a total of 10 TBMs in 26 late 2017 and early 2018. (Dkt. No. 53 at 1.) By January 2017, Mary Brown was the regional 1 director for the Northwest region. (Dkt. No. 51 at 8.) Plaintiff reported to Brown from 2017 to 2 2018. (Id. at 90.) 3 Plaintiff had experienced migraine headaches for about 10 years prior to the events in 4 question. (Dkt. No. 49 at 8.) While employed for Defendant, Plaintiff experienced very few 5 migraines while traveling for work. (Id. at 11.) On September 5, 2017, during a sales trip in 6 Alaska, she experienced a debilitating migraine. (Id. at 6–7.) Brown was with Plaintiff and 7 helped her through the migraine. (Id. at 53–54.) At a work event about a week later, James 8 Lykins, Plaintiff’s sales partner and fellow TBM, mentioned to Brown that Plaintiff had a 9 migraine on a different sales trip. (Id. at 13–14, 84–85.) Brown pulled Lykins aside and told him 10 that she appreciated his concern, but they should not be discussing Plaintiff’s medical condition. 11 (Dkt. No. 51 at 178.) Plaintiff maintains that following these incidents, Brown spoke to her on 12 multiple occasions about her migraine condition and became concerned about her ability to 13 travel for work. (Dkt. Nos. 49 at 10–11, 62 at 5.) Plaintiff also states that Brown recommended 14 she seek a different job. (Dkt. No. 49 at 10–11.) Brown asserts that she never made such a 15 statement and instead expressed support and offered possible accommodations. (See Dkt. No. 51 16 at 12, 59–62.) 17 While employed by Defendant, Plaintiff had been trained annually on her duty to report 18 suspected violations of the False Claims Act (“FCA”), 31 U.S.C. § 3729, by the off-label use, 19 promotion, or sale of prescription drugs. (Dkt. No. 49 at 24.) In 2017, Defendant marketed and 20 sold the drug Zinbryta. (Dkt. No. 1 at 2.) Zinbryta had been approved by the Food and Drug 21 Administration in a limited capacity—to treat multiple sclerosis patients who had an inadequate 22 response to other treatments. (Id. at 4.) It is a FCA violation to promote off-label use of 23 prescription drugs to Medicare patients. See 31 U.S.C. § 3729(a)(1); (Dkt. No. 49 at 25–26.) 24 Before a doctor can enroll a patient in certain drug therapy regimens, the doctor must 25 complete and submit a “START Form” to the pharmaceutical manufacturer. (See Dkt. No. 53 at 26 2.) Defendant’s Zinbryta START form requires the doctor to specify the patient’s diagnosis, 1 certify that the diagnosis is the rationale for prescribing the drug, and further certify that the 2 doctor will supervise the patient’s treatment accordingly. (Dkt. No. 64 at 209–10.) Defendant’s 3 Zinbryta START form is pre-filled with the International Classification of Disease (“ICD”) 4 codes for multiple sclerosis, and by signing the START form, the doctor “certifies that the 5 rationale for prescribing ZINBRYTA therapy is for a primary diagnosis of ICD-9:340/ICD- 6 10:G35.” (Id. at 209–10.) 7 In the fall of 2017, shortly after Plaintiff’s sales trip to Alaska, Lykins told Plaintiff that a 8 doctor had contacted him about providing Zinbryta to an aplastic anemia patient for off-label 9 use. (Dkt. No. 49 at 91.) Plaintiff told Lykins that she believed it would be improper for him to 10 deliver the forms because they involved an off-label use of Zinbryta. (Id.) In November 2017, 11 Plaintiff expressed her opposition to Lykins’s involvement with providing Zinbryta to the 12 aplastic anemia patient to Brown at a meeting with Western division manager Zachary Allison. 13 (Dkt. No. 51 at 102.) On November 17, 2017, Plaintiff was copied on an email that stated that 14 the patient’s insurance company had approved the patient for Zinbryta, and that Lykins planned 15 to deliver the START form so the patient could get enrolled. (Dkt. No. 55 at 2, 6–8.) On 16 December 6, 2017, Plaintiff submitted a complaint to Defendant’s ethics hotline to report Brown 17 and Lykins’s involvement with the off-label Zinbryta sale. (Id. at 102.) In her report, she also 18 stated she was in fear of retaliation by Brown for her opposition. (Dkt. No. 75 at 16.) Shortly 19 thereafter, Dan Curto, Defendant’s in-house counsel, followed up with Plaintiff about her ethics 20 complaint. (Id. at 16.) Curto also followed up with Brown about Plaintiff’s complaint. (Dkt. No. 21 64 at 72–73.) 22 In mid-January, Plaintiff contacted Defendant’s human resources partner Keri Palacio to 23 follow up further about the ethics complaint. (Dkt. No. 75 at 17.) On January 25, 2018, Plaintiff 24 spoke to Palacio about the ethics complaint. (Id.) Additionally, Plaintiff raised a new concern: 25 that Brown treated men more favorably than women. (Dkt. No. 62 at 2–3.) Plaintiff asserted she 26 had observed Brown favoring male TBMs over females, tending to call on them more, assigning 1 them to committees, supporting their promotions, and assigning them more advanced tasks. (Id.) 2 Plaintiff also maintains that she reported to Palacio that Brown had been treating her unfavorably 3 since Brown witnessed Plaintiff’s migraine. (Dkt. No. 51 at 76–77, 298.) Palacio denies that 4 Plaintiff reported that she had a migraine condition or that she was being treated differently 5 because of it. (Id. at 191, 194, 202–203.) 6 Defendant evaluated TBM performance every six months in the form of “OPR” ratings. 7 (Dkt. No. 64 at 74.) Plaintiff had consistently received competent 2/2 OPR ratings. (Id. at 65, 8 135.) In early 2018, Defendant decided to restructure its national workforce and determined that 9 some TBM positions would be eliminated due to a reduction in force. (Dkt. No. 20 at 2.) One of 10 the four TBM positions in Plaintiff’s territory was to be eliminated. (Dkt. No. 19 at 2.) On 11 January 31, 2018, Brown and Allison listed Plaintiff as a “bottom performer” identified for 12 “realignment,” i.e., termination. (Dkt. Nos. 64 at 44, 66 at 42–45.) In early February 2018, 13 Brown completed her review of Plaintiff’s performance for the second half of the previous year, 14 once again assigning Plaintiff a 2/2 OPR rating. (Id. at 65.) 15 In mid-February 2018, Defendant provided its managers three criteria to use in selecting 16 TBMs for termination: OPR ratings, sales competencies, and tenure. (Id. at 27, 29, 79–80; see 17 Dkt. No. 20 at 2.) Brown was responsible for rating the TBMs in her region and deciding whom 18 to terminate, with input from Palacio and Allison. (Dkt. No. 19 at 2.) On the first criterion, all 19 four TBMs had the same OPR rating of 2/2.

Free access — add to your briefcase to read the full text and ask questions with AI

Erickson v. Biogen, Inc, (W.D. Wash. 2019).

Erickson v. Biogen, Inc (Erickson v. Biogen, Inc) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Lujan v. National Wildlife Federation
497 U.S. 871 (Supreme Court, 1990)
Robert H. Michel v. Donnald K. Anderson
14 F.3d 623 (D.C. Circuit, 1994)
Vicki G. Paluck v. Gooding Rubber Company
221 F.3d 1003 (Seventh Circuit, 2000)
Dicomes v. State
782 P.2d 1002 (Washington Supreme Court, 1989)
Allison v. Housing Authority of City of Seattle
821 P.2d 34 (Washington Supreme Court, 1991)
Francom v. Costco Wholesale Corp.
991 P.2d 1182 (Court of Appeals of Washington, 2000)